drugset / Trial / NCT05416021
Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008
RandomizedCrossoverOpen-labelPrevention
Summary
A Phase I, Open-Label, Randomized, Crossover Trial to Investigate the Relative Bioavailability of the 25 mg Dapivirine Vaginal Ring-004 inserted every 30 days and 100 mg Dapivirine Vaginal Ring-008 inserted for 90 days in Healthy Female Participants
Timeline
- Start
- 2022-08-01
- Primary completion
- 2024-04-02
- Completion
- 2024-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | dapivirine | Small molecule | 25 mg | — |
| Comparator | dapivirine | Small molecule | 100 mg | — |